



# Identifying the Presence and Spread of COVID-19: Screening, Testing, and Contact Tracing

Jenny L. Johnson, PhD College of Pharmacy



## **Objectives**

#### Screening

Identify symptoms used for screening patients prior to COVID-19 tests.

#### Testing

Describe available testing options.

Discuss new testing strategies.

#### Contact Tracing

Categorize benefits and concerns associated with contact tracing.

# Screening



#### **Screening Symptomatic Patients**

Some testing facilities are only testing symptomatic patients
 May miss up to 40% of COVID-19+ patients

Patients with the following symptoms are recommended for testing:

New loss of taste or smell

Cough

Repeated shaking with chills (rigors)

Nausea or vomiting

Diarrhea

Fever

Difficulty breathing

Muscle pain

New onset fatigue

Headache

 People who have had close contact with someone with confirmed COVID-19 should also be tested

Within 6 feet for at least 15 minutes

# Testing




# **Available Testing Options-Diagnostic Tests**

• Two categories of COVID-19 tests

Molecular tests

Antigen tests








#### **Molecular Tests**

- Most accurate of two diagnostic test types
- Administered mostly through nasal/throat swabs Detects viral genetic material (RNA)
- Highly manual process

RT-PCR: involves hands-on time with each testing sample Can take a while to get results

- Over 100 companies have been authorized by the FDA for distribution
  - Provider-administered swab tests
  - At home testing kit (fully autonomous kits are not yet authorized by the FDA)







# **Available Testing Options-Diagnostic Tests**

#### Antigen Test

Nasal/throat swab

Faster: Results in an hour or less

Cheaper: Much less labor intensive

Higher chance of false negative results

Date EUA Issued	Manufacturer	\$ Diagnostic (Letter of Authorization)	<b></b>	Technology $\Rightarrow$	Authorized Setting(s) <sup>1</sup> \$	Authorization Documents <sup>2</sup> \$
08/26/2020	Abbott Diagnostics Scarborough, Inc.	BinaxNOW COVID-19 Ag Card		Antigen	H, M, W	HCP, Patients, IFU
08/18/2020	LumiraDx UK Ltd.	LumiraDx SARS-CoV-2 Ag Test		Antigen	H, M, W	HCP, Patients, IFU
07/02/2020	Becton, Dickinson and Company (BD)	BD Veritor System for Rapid Detection of SARS-CoV-2		Antigen	H, M, W	HCP, Patients, IFU
05/08/2020	Quidel Corporation	Sofia SARS Antigen FIA		Antigen	H, M, W	HCP, Patients, IFU



Images: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas#individual-antigen; https://www.nbcnews.com/health/health-news/abbott-s-5-rapid-covid-19-antigen-test-granted-authorization-n1238409




## **Antibody Tests**

- Finger stick or blood draw<sup>1</sup>
   Detects antibodies specific for the virus<sup>1</sup>
- Results given same day or up to 3 days later<sup>1</sup>
- Does <u>NOT</u> diagnose active infection<sup>1</sup>

Test could also detect cross-reactive antibodies from other coronaviruses<sup>1</sup>


- A positive antibody test does not mean that a patient is immune from future infection Second infections (with a different strain) have been documented<sup>2</sup>
- More informative for COVID-19 research<sup>1</sup>
  - Allows insight into the breadth of viral spread



<sup>1.</sup> https://time.com/5880255/covid-19-tests-types/

<sup>2.</sup> https://www.sciencemag.org/news/2020/08/some-people-can-get-pandemic-virus-twice-study-suggests-no-reason-panic Images: https://www.drugtargetreview.com/news/61620/antibody-named-s309-from-sars-patient-shows-promise-against-covid-19/https://www.roche.com/strongertogether/covid-19-antibodies-immunity.htm

# **LIHSC**






Sample loading

Add drop of serum (shown above in yellow) or blood in sample well (S).




2) Buffer loading

Add dilution phosphate saline buffer to sample well.




3) Sample incubation

Capillary action moves sample across lateral flow test.




4) Antibody-antigen recognition

Antibodies with specificity for COVID-19 bind to gold COVID-19-antigen conjugates in conjugate pad.




5) COVID-19 antibody detection

Sample enters testing well (T) and COVID-19 antibody-antigen complex binds to immobilized anti-human IgG/IgM antibodies.



6 Control antibody detection

Rabbit antibody-gold conjugate binds to immobilized anti-rabbit IgG antibodies.



7) Interpreting results


Positive: one strip each in C well and T well

Negative: one strip in C well



# **New Testing Strategies-Pooled Testing**

- Combines samples during analysis
  Reduces reagent use and time until results
- If a sample comes back negative:
   The entire pool is presumed negative
- If a sample comes back positive:
   The pool of patients is retested individually to find the positive patient within the pool





#### **New Testing Strategies-Saliva Tests**

Sample collection is less invasive than the traditional nasal swab

Patients can collect the sample at home.

Early research indicates that saliva tests are as accurate as the nasal

swab tests

Utilizes LAMP technology

A PCR alternative where all reactions take place at 63C, which does not require as much specialized equipment.



https://www.the-scientist.com/news-opinion/saliva-tests-how-they-work-and-what-they-bring-to-covid-19-67720

Image: https://www.discovermagazine.com/health/new-covid-19-saliva-tests-are-cheaper-and-faster-

than-nose-swabs-heres-how




# **New Testing Strategies-Flu/COVID-19 test**

 Muliplex assay (Flu SC2) testing for SARS-CoV2, Influenza A, and Influenza B simultaneously

Utilizes the same PCR technology as the traditional nasal swab tests.

FDA granted emergency use authorization on July 2, 2020

 Distribution of the tests began in August



# **Contact Tracing**



#### **Main Benefit**

#### Identifies potential exposures

Allows individuals to be better informed about potential exposure and seek testing

The health department will contact anyone who was in close contact (within 6 feet for more than 15 minutes) without sharing any names or identifying information

Individuals are contagious for at least 48 hours prior to symptom onset

Minimizes the spread of COVID-19





#### **Considerations**

- Personal health data potentially shared with employer, insurance, etc.
   All conversations with health departments are confidential
- As more contact tracing moves to a digital format, there is heightened concern about information security.

Digital tracking technology on smart phones (ie, tracking/monitoring apps), particularly Bluetooth-enabled devices, could be vulnerable to hacking

Contact tracers will never ask for information related to money, banking, or credit cards.



# **Questions?**

